Request Trial
15 January 2019Americas

McGuire Woods adds three partners to life sciences team

US law firm McGuire Woods is expanding its life sciences patent litigation team with the addition of three partners in its New York office.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
From the courtroom: Hikma v Amarin SCOTUS oral arguments
30 April 2026   The Supreme Court's first look at the skinny label dispute dug into key questions, from the role of the skinny label to who Hikma’s statements were really meant for, in one of the most important patent cases in years.
Americas
Blow for Masimo’s fight with Apple as case against US Customs dismissed
29 April 2026   The wearable tech company has had to drop its lawsuit against US Customs and Border Protection, part of the wider, ongoing dispute with Apple over a blood oxygen feature in smart watches.
Americas
Ligand buys biotech in $739m cash deal with litigation sweetener
28 April 2026   Pharma group strikes an all-cash transaction, combining a portfolio expansion with a contingent payment linked to a dispute over a $5 billion drug


Editor's picks

From the courtroom: Hikma v Amarin SCOTUS oral arguments
Americas
From the courtroom: Hikma v Amarin SCOTUS oral arguments
30 April 2026

Editor's picks

Americas
From the courtroom: Hikma v Amarin SCOTUS oral arguments
30 April 2026

More features

From the courtroom: Hikma v Amarin SCOTUS oral arguments
Report: 85% of in-house counsel want IP service providers to embrace AI
Moderna loses key mRNA patent in European vaccine fight
Boston-based patent expert departs Mintz for major West Coast firm
Blow for Masimo’s fight with Apple as case against US Customs dismissed
Ligand buys biotech in $739m cash deal with litigation sweetener
CureVac targets Moderna with 10-patent suit over Spikevax
Safeguarding critical IP in a high-risk era: WIPR Trade Secrets West 2026